Researcher
Nathalie Van den Berghe
- Disciplines:Molecular and cell biology
Affiliations
- Laboratory of Viral Cell Biology & Therapeutics (Division)
Member
From1 May 2022 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From28 Aug 2017 → 31 Dec 2021
Projects
1 - 1 of 1
- Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicalsFrom28 Aug 2017 → 31 Dec 2021Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 10
- The value of therapeutic drug monitoring to guide treatment optimisation of biologicals in patients with chronic inflammatory diseases: focus on vedolizumab and ustekinumab(2021)
Authors: Nathalie Van den Berghe, Paul Declerck, Séverine Vermeire, Debby Thomas
- Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations(2021)
Authors: Nathalie Van den Berghe, Bram Verstockt, João Pedro Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Paul Declerck, Debby Thomas
Pages: 988 - 993 - Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis(2020)
Authors: Nathalie Van den Berghe, Rani Soenen, Maya Imbrechts
Number of pages: 9 - Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations(2020)
Authors: Nathalie Van den Berghe, Séverine Vermeire, Marc Ferrante, Debby Thomas
Number of pages: 7 - Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis(2019)
Authors: Jessica Vandenhaute, Bert Malengier-Devlies, Maya Imbrechts, Nathalie Van den Berghe, Kourosh Ahmadzadeh, Carine Wouters, Patrick Matthys
Pages: 3339 - 3348Number of pages: 10 - Achieving mucosal healing in inflammatory bowel diseases: which drug concentrations need to be targeted?(2019)
Authors: Nathalie Van den Berghe, Ann Gils, Debby Thomas
Pages: 945 - 954Number of pages: 10 - Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy(2019)
Authors: Rani Soenen, Nathalie Van den Berghe, Ann Gils
Pages: 2232 - 2235Number of pages: 15 - Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis(2019)
Authors: Nathalie Van den Berghe, Ann Gils
Pages: 390 - 397Number of pages: 8 - Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients(2019)
Authors: Nathalie Van den Berghe, Bram Verstockt, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 1175 - 1181Number of pages: 7 - Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates(2019)
Authors: Bram Verstockt, Erwin Dreesen, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Gert Van Assche, Ann Gils, Séverine Vermeire, Marc Ferrante
Pages: 864 - 872Number of pages: 9